

# SENATE BILL 392

J1, C2

6lr1806  
CF HB 27

---

By: Senator King

Introduced and read first time: January 28, 2026

Assigned to: Finance

---

## A BILL ENTITLED

1 AN ACT concerning

2 **Maryland Technology Development Corporation – Long COVID Innovation**  
3 **Grant and Loan Program**

4 FOR the purpose of requiring the Maryland Technology Development Corporation to  
5 establish a grant and loan program to provide grants and loans for Long COVID  
6 innovation; requiring the Corporation to contract with an independent review  
7 committee composed of scientific experts in the field of Long COVID; establishing  
8 the Maryland Long COVID Research Fund under the administration of the  
9 Corporation as a special, nonlapsing fund; requiring that the interest earnings of the  
10 Fund be credited to the Fund; and generally relating to a Long COVID grant and  
11 loan program.

12 BY repealing and reenacting, without amendments,  
13 Article – Economic Development  
14 Section 10–401(a) and (c)  
15 Annotated Code of Maryland  
16 (2024 Replacement Volume and 2025 Supplement)

17 BY adding to  
18 Article – Economic Development  
19 Section 10–4E–01 through 10–4E–07 to be under the new subtitle “Subtitle 4E. Long  
20 COVID Innovation Grant and Loan Program”  
21 Annotated Code of Maryland  
22 (2024 Replacement Volume and 2025 Supplement)

23 BY repealing and reenacting, without amendments,  
24 Article – State Finance and Procurement  
25 Section 6–226(a)(2)(i) and (ii)  
26 Annotated Code of Maryland  
27 (2021 Replacement Volume and 2025 Supplement)

---

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.



1 BY repealing and reenacting, with amendments,  
2 Article – State Finance and Procurement  
3 Section 6–226(a)(2)(iii)212. and 213.  
4 Annotated Code of Maryland  
5 (2021 Replacement Volume and 2025 Supplement)

6 BY adding to  
7 Article – State Finance and Procurement  
8 Section 6–226(a)(2)(iii)214.  
9 Annotated Code of Maryland  
10 (2021 Replacement Volume and 2025 Supplement)

11 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,  
12 That the Laws of Maryland read as follows:

13 **Article – Economic Development**

14 10–401.

15 (a) In this subtitle the following words have the meanings indicated.  
16 (c) “Corporation” means the Maryland Technology Development Corporation.

17 **SUBTITLE 4E. LONG COVID INNOVATION GRANT AND LOAN PROGRAM.**

18 **10–4E–01.**

19 (A) IN THIS SUBTITLE THE FOLLOWING WORDS HAVE THE MEANINGS  
20 INDICATED.

21 (B) “COMMITTEE” MEANS THE INDEPENDENT SCIENTIFIC PEER REVIEW  
22 COMMITTEE WITH WHICH THE CORPORATION CONTRACTS UNDER § 10–4E–04 OF  
23 THIS SUBTITLE.

24 (C) “CORPORATION” HAS THE MEANING STATED IN § 10–401 OF THIS TITLE.

25 (D) “FUND” MEANS THE MARYLAND LONG COVID RESEARCH FUND.

26 (E) “LONG COVID” HAS THE MEANING:

27 (1) ESTABLISHED BY THE NATIONAL ACADEMY OF SCIENCES IN “A  
28 LONG COVID DEFINITION: A CHRONIC, SYSTEMIC DISEASE STATE WITH  
29 PROFOUND CONSEQUENCES” PUBLISHED IN 2024; OR

4 (F) "LONG COVID INNOVATION" MEANS RESEARCH, PRODUCT  
5 DEVELOPMENT, AND MANUFACTURING IN THE STATE RELATED TO TREATMENT OF  
6 LONG COVID AND CONDUCTED WITH MONEY FROM THE FUND.

(G) "PROGRAM" MEANS THE GRANT AND LOAN PROGRAM ESTABLISHED BY THE CORPORATION UNDER § 10-4E-02 OF THIS SUBTITLE.

9 10-4E-02.

10 THE CORPORATION SHALL ESTABLISH A GRANT AND LOAN PROGRAM TO  
11 PROVIDE GRANTS AND LOANS FOR STATE-FUNDED LONG COVID INNOVATION.

12 10-4E-03.

1                   **(B) THE CORPORATION MAY CONSULT WITH EXPERTS IN PERFORMING ITS**  
2 **DUTIES.**

3 **10-4E-04.**

4                   **(A) THE CORPORATION SHALL CONTRACT WITH AN INDEPENDENT REVIEW**  
5 **COMMITTEE COMPOSED OF SCIENTIFIC EXPERTS IN THE FIELD OF LONG COVID**  
6 **INNOVATION.**

7                   **(B) THE COMMITTEE SHALL:**

8                   **(1) REVIEW, EVALUATE, RANK, AND RATE RESEARCH PROPOSALS FOR**  
9 **STATE-FUNDED LONG COVID INNOVATION:**

10                   **(I) BASED ON THE PROCEDURES AND GUIDELINES**  
11 **ESTABLISHED BY THE CORPORATION; AND**

12                   **(II) IN A MANNER THAT GIVES DUE CONSIDERATION TO THE**  
13 **SCIENTIFIC, MEDICAL, AND ETHICAL IMPLICATIONS OF THE RESEARCH; AND**

14                   **(2) BASED ON THE RANKINGS AND RATINGS AWARDED TO THE**  
15 **RESEARCH PROPOSALS, MAKE RECOMMENDATIONS TO THE CORPORATION FOR THE**  
16 **AWARD AND DISBURSEMENT OF GRANTS AND LOANS.**

17                   **(C) A MEMBER OF THE COMMITTEE:**

18                   **(1) IS NOT ELIGIBLE TO RECEIVE A GRANT OR LOAN FOR**  
19 **STATE-FUNDED LONG COVID INNOVATION FROM THE FUND; AND**

20                   **(2) SHALL BE SUBJECT TO THE POLICIES AND PROCEDURES**  
21 **GOVERNING CONFLICTS OF INTEREST ESTABLISHED BY THE CORPORATION UNDER**  
22 **§ 10-4E-03(A)(6) OF THIS SUBTITLE.**

23 **10-4E-05.**

24                   **(A) THERE IS A MARYLAND LONG COVID RESEARCH FUND.**

25                   **(B) THE PURPOSE OF THE FUND IS TO PROMOTE STATE-FUNDED LIFE**  
26 **SCIENCES RESEARCH, DEVELOPMENT, COMMERCIALIZATION, AND**  
27 **MANUFACTURING IN THE STATE RELATED TO LONG COVID THROUGH GRANTS AND**  
28 **LOANS TO PUBLIC AND PRIVATE ENTITIES IN THE STATE.**

29                   **(C) THE CORPORATION SHALL ADMINISTER THE FUND.**

1                   (D) (1) THE FUND IS A SPECIAL, NONLAPSING FUND THAT IS NOT  
2 SUBJECT TO § 7-302 OF THE STATE FINANCE AND PROCUREMENT ARTICLE.

3                   (2) THE STATE TREASURER SHALL HOLD THE FUND SEPARATELY,  
4 AND THE COMPTROLLER SHALL ACCOUNT FOR THE FUND.

5                   (E) THE FUND CONSISTS OF:

6                   (1) MONEY APPROPRIATED IN THE STATE BUDGET TO THE FUND;

7                   (2) INTEREST EARNINGS OF THE FUND; AND

8                   (3) ANY OTHER MONEY FROM ANY OTHER SOURCE ACCEPTED FOR  
9 THE BENEFIT OF THE FUND.

10                  (F) MONEY IN THE FUND MAY BE USED ONLY TO:

11                  (1) AWARD GRANTS AND LOANS FOR STATE-FUNDED LONG COVID  
12 INNOVATION; AND

13                  (2) PAY THE COSTS NECESSARY TO ADMINISTER THE FUND.

14                  (G) (1) THE STATE TREASURER SHALL INVEST THE MONEY IN THE FUND  
15 IN THE SAME MANNER AS OTHER STATE MONEY MAY BE INVESTED.

16                  (2) ANY INTEREST EARNINGS OF THE FUND SHALL BE CREDITED TO  
17 THE FUND.

18                  (H) (1) EACH FISCAL YEAR, THE GOVERNOR MAY INCLUDE IN THE  
19 ANNUAL BUDGET BILL AN APPROPRIATION TO THE FUND.

20                  (2) EXPENDITURES FROM THE FUND MAY BE MADE ONLY IN  
21 ACCORDANCE WITH THE STATE BUDGET.

22                  10-4E-06.

23                  THE CORPORATION SHALL ADOPT REGULATIONS TO:

24                  (1) ESTABLISH PROCEDURES FOR AWARDING AND MAKING THE  
25 DISBURSEMENT OF A GRANT OR LOAN UNDER THE PROGRAM;

4 10-4E-07.

10 (B) THE REPORT SHALL IDENTIFY:

11 (1) EACH RECIPIENT OF A GRANT OR LOAN AWARDED UNDER THE  
12 PROGRAM;

**(2) THE AMOUNT OF FUNDING AWARDED TO EACH RECIPIENT;**

16 (4) INDICATORS OF THE ECONOMIC IMPACT OF GRANTS AND LOANS  
17 MADE FROM THE FUND; AND

18 (5) ANY RECOMMENDATIONS FOR IMPROVING THE OVERALL  
19 EFFECTIVENESS OF THE PROGRAM.

## Article – State Finance and Procurement

21 6-226.

22 (a) (2) (i) This paragraph does not apply in fiscal years 2024 through 2028.

1 212. the Department of Social and Economic Mobility Special  
2 Fund; [and]

3 213. the Population Health Improvement Fund; AND

## 214. THE MARYLAND LONG COVID RESEARCH FUND.

5 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect July  
6 1, 2026.